Skip to content
DataLookout
Start free
Menu

BEGINNCT06272864

BostonGene and Exigent Genomic INsight Study

StatusRecruiting
PhaseNot specified
SponsorBostonGene
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

See at-risk trials from BostonGene

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 8, 2026 to Jan 8, 2028
    • Eligibility criteria expanded, about 6 words
    • Study sites: 7 to 6
  2. Site contacts updated at 1 of 7 sitesv5
  3. Study sites: 1 to 7v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 8, 2024 to Apr 8, 2024
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Frequency of actionable findings
Timeframe: 2 years
Test turn-around time
Timeframe: 2 years

Secondary (1)

Frequency of patients who receive molecularly matched therapy

Arms and interventions

Breast cancer

Patients with locally recurrent, unresectable or metastatic breast cancer

NSCLC

Patients with unresectable stage III or metastatic non-small cell lung cancer

Melanoma

Patients with unresectable or metastatic melanoma

Sarcoma

Patients with locally advanced or metastatic sarcoma

Sites

6 sites in 1 country